Obermatt
See Similar Stocks →

Tarsus Pharmaceuticals

NSQ:TARS · US87650L1035
PharmaceuticalsMedium

360

29
Profit price97
Owner Earnings Yield1
Dividend Yield1
Price/Sales46
EV / Gross Profit45
Price/Book17
Return on Capital23
Cash Return on Capital20
Return on Equity22
EBIT Margin4
Gross Profitability96
Accruals37
Owner Earnings Margin11
Sales growth91
Profit growth53
Reinvestment17
Price momentum65
Debt load59
Refinancing54
Debt Payback1
Liquidity29
Analyst ratings91
Opinion Changes50
Price Target Upside62
Market mood71
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Tarsus Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2016
Employees361
Websitetarsusrx.com
ISINUS87650L1035
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesDermatologyOphthalmologyBiopharmaBiotechnologyLife Science

Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutics, starting with eye care. The company launched XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known a…

Analysis

Weak and unloved

Tarsus Pharmaceuticals, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is fragile. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
91
2023202420252026

All-time high

91

Jun 2026

All-time low

3

Jan 2023

Average rank

51

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
46
11
3
4
Price/Earnings
97
26
26
26
Price/Book
17
13
23
46
Dividend Yield
1
1
1
1
Value (overall)
44
8
6
17

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tarsus Pharmaceuticals with its peers
Novavax
NSQ:NVAX
23
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →